Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission
Portfolio Pulse from
Achieve Life Sciences has reached a critical milestone in its ORCA-OL clinical trial for Cytisinicline, with over 300 participants completing six months of treatment. This fulfills the long-term exposure requirement for NDA submission.
January 07, 2025 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Achieve Life Sciences has successfully completed a key milestone in its ORCA-OL trial, with over 300 participants completing six months of Cytisinicline treatment. This achievement is crucial for the NDA submission process.
The completion of the long-term exposure requirement in the ORCA-OL trial is a significant step towards the NDA submission for Cytisinicline. This progress is likely to positively impact ACHV's stock price as it indicates advancement in the drug's regulatory process.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100